Overview

With broad and comprehensive capabilities, Waisman Biomanufacturing is uniquely situated and highly qualified to lead clients through the complex process of bringing a novel vaccines and therapeutics into the clinic. Our Industry-Academia hybrid operational model starts with an industry-experienced leadership team that negotiates a flexible and time and cost-effective development plan that meets your needs. 

Subsequently, our highly collaborative Process Development, Manufacturing, and Quality Control scientific team works to translate your bench top process to a scalable biopharmaceutical manufacturing process. Using this strategy Waisman routinely produces CGMP grade material suitable for human clinical trials for a wide variety of applications.